Is Eli Lilly Stock a No-Brainer Buy After Its FDA Alzheimer's Disease Drug Win?
How does Eli Lilly (NYSE: LLY) follow up on gains of close to 60% in 2023 and so far in 2024? By winning a major U.S. Food and Drug Administration (FDA) approval.
Last week, the FDA approved Lilly's Kisunla (donanemab) in treating early symptomatic Alzheimer's disease. Is Eli Lilly stock a no-brainer buy after this key FDA approval?
There are now eight FDA-approved treatments for Alzheimer's disease. That might seem like a crowded market, but Kisunla should have a significant commercial opportunity.
Source Fool.com